Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy

CD27 is a costimulatory molecule that provides a complementary target to the PD-1/PD-L1 checkpoint axis on T cells. Combining a CD27 agonist antibody with PD-1/PD-L1 blockade has shown synergistic antitumor activity in preclinical models, which led to clinical studies of the combination in cancer pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Laura A., He, Li-Zhen, Thomas, Lawrence J., Wasiuk, Anna, O’Neill, Thomas, Widger, Jenifer, Crocker, Andrea, Mills-Chen, Laura, Forsberg, Eric, Weidlick, Jeffrey, Patterson, Colleen, Hammond, Russell A., Boyer, James, Sisson, Crystal, Alvarado, Diego, Goldstein, Joel, Marsh, Henry C., Keler, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511290/
https://www.ncbi.nlm.nih.gov/pubmed/32451681
http://dx.doi.org/10.1007/s00262-020-02610-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511290/
https://www.ncbi.nlm.nih.gov/pubmed/32451681
http://dx.doi.org/10.1007/s00262-020-02610-y

Ejemplares similares